SCHEMBL3576249

SCHEMBL3576249

Ic1cccc(OC2CCCCO2)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.48
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HSD11B1 P28845 1/20 0.42
KDM4C Q9H3R0 1/20 0.39
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TNK2 Q07912 1/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.32
ACP1 P24666 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3184997 0.89 DHFR (0.53) DHFRSLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL7233566 0.81 DHFR (0.48) DHFRSLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL30812310 0.81 DHFR (0.48) DHFRSLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL29642714 0.81 DHFR (0.48) DHFRSLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL1025178 0.81 DHFR (0.54) DHFRHSD11B1KDM4CTNK2RAB9A
SCHEMBL23975531 0.81 DHFR (0.48) DHFRHSD11B1KDM4CMEN1KMT2A
SCHEMBL2205861 0.81 DHFR (0.48) DHFRSLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL5987851 0.81 DHFR (0.48) DHFRSLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL5546439 0.81 DHFR (0.48) DHFRHSD11B1KDM4CMEN1KMT2A
SCHEMBL5642512 0.81 DHFR (0.48) DHFRSLC6A2SLC6A4SLC6A3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112390802-A Pyrrolopyrazole derivative, preparation method and medical application thereof 上海美迪西生物医药股份有限公司 2021-02-23 CN disclosed
US-7683168-B2 Compositions of novel opioid compounds and method of use thereof Mount Cook Bio Sciences, Inc. (US) 2010-03-23 US disclosed
US-7683168-B2 Compositions of novel opioid compounds and method of use thereof Mount Cook Bio Sciences, Inc. (US) 2010-03-23 US disclosed
US-7683168-B2 Compositions of novel opioid compounds and method of use thereof Mount Cook Bio Sciences, Inc. (US) 2010-03-23 US disclosed
EP-1874315-A2 COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF Mount Cook Biosciences, Inc. (US) 2008-01-09 EP disclosed
US-20070043028-A1 Compositions of novel opioid compounds and method of use thereof DMK PHARMACEUTICALS CORPORATION 2007-02-22 US disclosed
US-20070043028-A1 Compositions of novel opioid compounds and method of use thereof DMK PHARMACEUTICALS CORPORATION 2007-02-22 US disclosed
US-20070043028-A1 Compositions of novel opioid compounds and method of use thereof DMK PHARMACEUTICALS CORPORATION 2007-02-22 US disclosed
WO-2006113468-A2 COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF MOUNT COOK BIOSCIENCES, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043028-A1 Compositions of novel opioid compounds and method of use thereof OPRL1, OPRD1, OPRK1 DHFR 4630/4885SLC6A2 1320/4885SLC6A4 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.